Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Status:
RECRUITING
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy